Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice

Molecular Therapy Methods and Clinical Development

Volumn 3, Issue , 2016, Pages 16064-

  Lange, Amy M ^a,b   Altynova, Ekaterina S ^b   Nguyen, Giang N ^a   Sabatino, Denise E ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; ALANINE AMINOTRANSFERASE; BLOOD CLOTTING FACTOR 8; CASPASE 3; IMMUNOGLOBULIN G ANTIBODY;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION; GENE OVEREXPRESSION; HEAVY CHAIN; HEMOPHILIA A; HYDRODYNAMICS BASED TRANSFECTION; IMMUNE RESPONSE; LIGHT CHAIN; LIVER FUNCTION; LIVER TISSUE; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENE; UNFOLDED PROTEIN RESPONSE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 85015236525     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2016.64     Document Type: Article

References (41)

1. 1 Peyvandi, F, Garagiola, I, Young, G, The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet 388 (2016), 187–197.
2. 2 Nathwani, AC, Tuddenham, EG, Rangarajan, S, Rosales, C, McIntosh, J, Linch, DC, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365 (2011), 2357–2365.
3. 3 Nathwani, AC, Reiss, UM, Tuddenham, EG, Rosales, C, Chowdary, P, McIntosh, J, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 371 (2014), 1994–2004.
4. 4 George, LA, Fogarty, PF, Gene therapy for hemophilia: past, present and future. Semin Hematol 53 (2016), 46–54.
5. 5 Sabatino, DE, Lange, AM, Altynova, ES, Sarkar, R, Zhou, S, Merricks, EP, et al. Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors. Mol Ther 19 (2011), 442–449.
6. 6 Brown, HC, Wright, JF, Zhou, S, Lytle, AM, Shields, JE, Spencer, HT, et al. Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery. Mol Ther Methods Clin Dev, 1, 2014, 14036.
7. 7 Jiang, H, Lillicrap, D, Patarroyo-White, S, Liu, T, Qian, X, Scallan, CD, et al. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood 108 (2006), 107–115.
8. 8 McIntosh, J, Lenting, PJ, Rosales, C, Lee, D, Rabbanian, S, Raj, D, et al. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood 121 (2013), 3335–3344.
9. 9 Anguela, XM, Elkouby, L, Toso, R, DiPietro, M, Davidson, RJ, High, KA, et al. Adeno-associated viral vector delivery of optimized human factor VIII achieves therapeutic factor VIII levels in non-human primates. Blood, 126(23), 2015, 199.
10. 10 Pittman, DD, Alderman, EM, Tomkinson, KN, Wang, JH, Giles, AR, Kaufman, RJ, Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood 81 (1993), 2925–2935.
11. 11 Pipe, SW, Morris, JA, Shah, J, Kaufman, RJ, Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin. J Biol Chem 273 (1998), 8537–8544.
12. 12 Kaufman, RJ, Pipe, SW, Tagliavacca, L, Swaroop, M, Moussalli, M, Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis 8:Suppl 2 (1997), S3–14.
13. 13 Kaufman, RJ, Wasley, LC, Dorner, AJ, Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem 263 (1988), 6352–6362.
14. 14 Zhang, K, Kaufman, RJ, From endoplasmic-reticulum stress to the inflammatory response. Nature 454 (2008), 455–462.
15. 15 Pittman, DD, Tomkinson, KN, Kaufman, RJ, Post-translational requirements for functional factor V and factor VIII secretion in mammalian cells. J Biol Chem 269 (1994), 17329–17337.
16. 16 Malhotra, JD, Miao, H, Zhang, K, Wolfson, A, Pennathur, S, Pipe, SW, et al. Antioxidants reduce endoplasmic reticulum stress and improve protein secretion. Proc Natl Acad Sci USA 105 (2008), 18525–18530.
17. 17 Brown, HC, Gangadharan, B, Doering, CB, Enhanced biosynthesis of coagulation factor VIII through diminished engagement of the unfolded protein response. J Biol Chem 286 (2011), 24451–24457.
18. 18 Staber, JM, Pollpeter, MJ, Arensdorf, A, Sinn, PL, Rutkowski, DT, McCray, PB Jr, piggyBac-mediated phenotypic correction of factor VIII deficiency. Mol Ther Methods Clin Dev, 1, 2014, 14042.
19. 19 Scallan, CD, Liu, T, Parker, AE, Patarroyo-White, SL, Chen, H, Jiang, H, et al. Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII. Blood 102 (2003), 3919–3926.
20. 20 Wang, Q, Dong, B, Firrman, J, Roberts, S, Moore, AR, Cao, W, et al. Efficient production of dual recombinant adeno-associated viral vectors for factor VIII delivery. Hum Gene Ther Methods 25 (2014), 261–268.
21. 21 Zhang, K, Kaufman, RJ, Identification and characterization of endoplasmic reticulum stress-induced apoptosis in vivo. Methods Enzymol 442 (2008), 395–419.
22. 22 Cao, O, Hoffman, BE, Moghimi, B, Nayak, S, Cooper, M, Zhou, S, et al. Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. Mol Ther 17 (2009), 1733–1742.
23. 23 Fields, PA, Arruda, VR, Armstrong, E, Chu, K, Mingozzi, F, Hagstrom, JN, et al. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. Mol Ther 4 (2001), 201–210.
24. 24 Matsui, H, Shibata, M, Brown, B, Labelle, A, Hegadorn, C, Andrews, C, et al. A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3+ T regulatory cells. Blood 114 (2009), 677–685.
25. 25 Mah, C, Sarkar, R, Zolotukhin, I, Schleissing, M, Xiao, X, Kazazian, HH, et al. Dual vectors expressing murine factor VIII result in sustained correction of hemophilia A mice. Hum Gene Ther 14 (2003), 143–152.
26. 26 Ward, NJ, Buckley, SM, Waddington, SN, Vandendriessche, T, Chuah, MK, Nathwani, AC, et al. Codon optimization of human factor VIII cDNAs leads to high-level expression. Blood 117 (2011), 798–807.
27. 27 Miao, HZ, Sirachainan, N, Palmer, L, Kucab, P, Cunningham, MA, Kaufman, RJ, et al. Bioengineering of coagulation factor VIII for improved secretion. Blood 103 (2004), 3412–3419.
28. 28 Siner, JI, Iacobelli, NP, Sabatino, DE, Ivanciu, L, Zhou, S, Poncz, M, et al. Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype. Blood 121 (2013), 4396–4403.
29. 29 Everett, LA, Cleuren, AC, Khoriaty, RN, Ginsburg, D, Murine coagulation factor VIII is synthesized in endothelial cells. Blood 123 (2014), 3697–3705.
30. 30 Fahs, SA, Hille, MT, Shi, Q, Weiler, H, Montgomery, RR, A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII. Blood 123 (2014), 3706–3713.
31. 31 Doering, CB, Denning, G, Dooriss, K, Gangadharan, B, Johnston, JM, Kerstann, KW, et al. Directed engineering of a high-expression chimeric transgene as a strategy for gene therapy of hemophilia A. Mol Ther 17 (2009), 1145–1154.
32. 32 Du, LM, Nurden, P, Nurden, AT, Nichols, TC, Bellinger, DA, Jensen, ES, et al. Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A. Nat Commun, 4, 2013, 2773.
33. 33 Greene, TK, Wang, C, Hirsch, JD, Zhai, L, Gewirtz, J, Thornton, MA, et al. In vivo efficacy of platelet-delivered, high specific activity factor VIII variants. Blood 116 (2010), 6114–6122.
34. 34 Schroeder, JA, Chen, Y, Fang, J, Wilcox, DA, Shi, Q, In vivo enrichment of genetically manipulated platelets corrects the murine hemophilic phenotype and induces immune tolerance even using a low multiplicity of infection. J Thromb Haemost 12 (2014), 1283–1293.
35. 35 Ozelo, MC, Vidal, B, Brown, C, Notley, C, Hegadorn, C, Webster, S, et al. Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune response. Blood 123 (2014), 4045–4053.
36. 36 Zanolini, D, Merlin, S, Feola, M, Ranaldo, G, Amoruso, A, Gaidano, G, et al. Extrahepatic sources of factor VIII potentially contribute to the coagulation cascade correcting the bleeding phenotype of mice with hemophilia A. Haematologica 100 (2015), 881–892.
37. 37 Finn, JD, Ozelo, MC, Sabatino, DE, Franck, HW, Merricks, EP, Crudele, JM, et al. Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood 116 (2010), 5842–5848.
38. 38 Greene, TK, Lyde, RB, Bailey, SC, Lambert, MP, Zhai, L, Sabatino, DE, et al. Apoptotic effects of platelet factor VIII on megakaryopoiesis: implications for a modified human FVIII for platelet-based gene therapy. J Thromb Haemost 12 (2014), 2102–2112.
39. 39 Bi, L, Sarkar, R, Naas, T, Lawler, AM, Pain, J, Shumaker, SL, et al. Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood 88 (1996), 3446–3450.
40. 40 Bi, L, Lawler, AM, Antonarakis, SE, High, KA, Gearhart, JD, Kazazian, HH Jr, Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 10 (1995), 119–121.
41. 41 Herzog, RW, Mount, JD, Arruda, VR, High, KA, Lothrop, CD Jr, Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol Ther 4 (2001), 192–200.